Dr. Papadimitrakopoulou, M.D. is the Jay and Lori Eisenberg Distinguished Professor of Medicine and Chief of the section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas/MD Anderson Cancer Center. Dr. Papadimitrakopoulou is nationally recognized for her
leadership and expertise in lung cancer treatment and research and best known for her work in personalized therapy of non-small cell lung cancer, in particular the process of linking cancer biomarkers to novel therapies. She is a member of the American Association for Cancer Research (AACR), as well as the American Society of Clinical Oncology where she has served as member of Scientific Committee and member of the Education Committee. She is a member of the Southwest Oncology Group’s lung committee, and a member of the membership and publications committees for the International Association for the Study of Lung Cancer. She has authored more than 140 peer-reviewed papers and has in the past received awards from the American Society of Clinical Oncology (YIA and CDA) and holds current grant funding for her work from numerous sources including the National Cancer Institute, and multiple charitable foundations.
Her primary interest is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to lung cancer patients. She has conducted translational research studies with particular focus on cell cycle regulation and signal transduction in both premalignant lesions and established cancer. Dr.
Papadimitrakopoulou has been the principal investigator on over 50 Phase I and II clinical trials with novel targeted agents including cell cycle inhibitors, farnesyl transferase inhibitors, pro-drugs, tyrosine kinase inhibitors, immunotherapy and chemoprevention studies. She led the BATTLE-2 trial a biomarker-driven multi-investigator clinical trial and is currently the national leader of the Lung MAP trial, a unique private-public partnership, using a diagnostic next-generation sequencing assay as a screening tool for an umbrella project aiming at approval of targeted therapies and immunotherapies in the context of refractory to standard therapy squamous lung cancer and sponsored by the NCI, NCTN.
She is a member of the Editorial Boards of Annals of Oncology, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Prevention, Cancer, and Clinical Cancer Research. Dr. Papadimitrakopoulou received her medical degree from The University of Patras Medical School in Greece and completed her internal medicine residency at Columbia Presbyterian Medical Center and her medical oncology fellowship at the University of Texas/MD Anderson Cancer Center and has completed a graduate certificate in health care management at Rice University.